- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative arthritis
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Tofacitinib – March 2020
Tofacitinib: Tablet 5 mg; Xeljanz®
Last updated
17 July 2020